Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors
March 01 2019 - 8:00AM
Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage
biopharmaceutical company developing innovative therapies to
improve patient outcomes in cancers that are difficult to treat,
today announced the appointment of Lara S. Sullivan, M.D. to its
board of directors.
Dr. Sullivan will chair a newly formed business development
committee, which has been established to assist the board with its
oversight of Rexahn’s business development activities with the goal
of maximizing the value of the company’s current and future
development programs. Dr. Sullivan will also serve on the
nominating and corporate governance committee.
“We are pleased to add Lara to the Rexahn board. She
brings a depth of experience that we believe will add significant
value to our board and Company,” said Peter Brandt, chairman of the
board of directors.
Dr. Sullivan added, “I am honored to join the Rexahn board and
look forward to bringing my clinical strategy, financial, and
operational experience and expertise to serve Rexahn’s board and
management.”
Lara Sullivan brings more than two decades of experience and
senior leadership in biopharmaceuticals, healthcare and life
sciences, to Rexahn. Dr. Sullivan is a founder and from 2017
to 2018 served as president of SpringWorks Therapeutics, a
clinical-stage biopharmaceutical company. Prior to joining
SpringWorks Therapeutics, Dr. Sullivan served as a vice president
of Pfizer from 2011 to 2017. While at Pfizer she helmed strategy
and portfolio operations for the company’s early-stage pipeline and
led the work, inside Pfizer and with outside patient groups and
partners, to create SpringWorks Therapeutics. Prior to
joining Pfizer, Dr. Sullivan was an associate principal in the
pharmaceutical and medical products practice at McKinsey &
Company, where she advised biopharmaceutical clients on a variety
of strategic and operational issues, with a particular emphasis on
research and development productivity. Dr. Sullivan also served as
a principal at Paul Capital Partners, where she led due diligence
for investments in their healthcare fund, and earlier in her career
worked in healthcare equity research and municipal finance at
Credit Suisse First Boston. Dr. Sullivan holds an M.D. from the
University of Pennsylvania School of Medicine, an MBA from The
Wharton School at the University of Pennsylvania, and a B.A. in
comparative literature from Cornell University.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals Inc. (NYSE American: RNN) is a clinical
stage biopharmaceutical company developing innovative therapies to
improve patient outcomes in cancers that are difficult to treat.
The company's mission is to improve the lives of cancer patients by
developing next-generation cancer therapies that are designed to
maximize efficacy while minimizing the toxicity and side effects
traditionally associated with cancer treatment. Rexahn's product
candidates work by targeting and neutralizing specific proteins
believed to be involved in the complex biological cascade that
leads to cancer cell growth. Preclinical studies show that certain
of Rexahn's product candidates may be effective against multiple
types of cancer, including drug resistant cancers, and
difficult-to-treat cancers, and others may augment the
effectiveness of current FDA-approved cancer treatments. The
company has two oncology product candidates, RX-3117 and RX-5902,
in Phase 2 clinical development and additional compounds in
preclinical development including RX-0301. For more information
about the Company and its oncology programs, please
visit www.rexahn.com.
Safe Harbor
To the extent any statements made in this press release deal
with information that is not historical, these are forward-looking
statements under the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about Rexahn's plans, objectives, expectations and intentions with
respect to Rexahn’s business development committee, the path of
clinical trials and development activities, and other statements
identified by words such as “will,” “potential,” “could,” “can,”
“believe,” “intends,” “continue,” “plans,” “expects,”
“anticipates,” “estimates,” “may,” other words of similar meaning
or the use of future dates. Forward-looking statements by their
nature address matters that are, to different degrees, uncertain.
Uncertainties and risks may cause Rexahn’s actual results to be
materially different than those expressed in or implied by Rexahn’s
forward-looking statements. For Rexahn, particular uncertainties
and risks include, among others, understandings and beliefs
regarding the role of certain biological mechanisms and processes
in cancer; drug candidates being in early stages of development,
including clinical development; the costs and timelines associated
with clinical development; the ability to transition from our
initial focus on developing drug candidates for orphan indications
to candidates for more highly prevalent indications; and the
expecting timing of results from our clinical trials. More detailed
information on these and additional factors that could affect
Rexahn’s actual results are described in Rexahn’s filings with the
Securities and Exchange Commission, including its most recent
annual report on Form 10-K and subsequent quarterly reports on Form
10-Q. All forward-looking statements in this news release speak
only as of the date of this news release. Rexahn undertakes no
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Media Contact:DGI CommSusan Forman or Laura
Radocaj
+1-212-825-3210sforman@dgicomm.comlradocaj@dgicomm.com
Investor contact:ir@rexahn.com
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Apr 2023 to Apr 2024